Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29846174 | 1.00 | CHRNB2 (0.47) | CHRNB2CHRNA4CA12CA1CA2 | |
| SCHEMBL15577521 | 0.82 | ALDH1A1 (0.39) | CHRNB2CHRNA4HTTCRHR1ALDH1A1 | |
| SCHEMBL18348155 | 0.81 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL9628 | 0.80 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL31637979 | 0.80 | BRD4 (0.36) | CHRNB2CHRNA4POLBTUBB1ALDH1A1 | |
| SCHEMBL29178978 | 0.79 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3HTT | |
| SCHEMBL13500442 | 0.78 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL5942438 | 0.78 | ALDH1A1 (0.36) | CHRNB2CHRNA4CRHR1ALDH1A1CYP3A4 | |
| SCHEMBL15918437 | 0.77 | PDE4A (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL8648769 | 0.77 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108148055-A | A kind of D- π-A types organic fluorescence materials and preparation method based on naphthalene | 陕西师范大学 | 2018-06-12 | — | — | CN | claimed |
| EP-4652164-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2024233812-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-116891468-A | Thiazole compound and application thereof | 南京再明医药有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230203214-A1 | AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203214-A1 | AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-06-29 | — | — | US | disclosed |
| CN-112074521-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2021233800-A1 | AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2021-11-25 | — | — | WO | disclosed |
| CN-112074521-A | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2020-12-11 | — | — | CN | disclosed |
| US-20100048591-A1 | CHEMICAL COMPOUNDS AND PROCESSES | BIONOMICS LIMITED (AU) | 2010-02-25 | — | — | US | disclosed |
| WO-2008070908-A1 | CHEMICAL COMPOUNDS AND PROCESSES | BIONOMICS LIMITED (AU) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008070908-A1 | CHEMICAL COMPOUNDS AND PROCESSES | BIONOMICS LIMITED (AU) | 2008-06-19 | — | — | WO | disclosed |
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | WELLSTAT BIOCATALYSIS, LLC | 2005-06-09 | — | — | US | disclosed |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | IGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| CN-1217335-A | Method for preparing precursor medicine | IGEN INC (US) | 1999-05-26 | — | — | CN | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| CN-1070409-A | Prodrugs activated by targetted catalytic proteins | IGEN INC (US) | 1993-03-31 | — | — | CN | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048591-A1 | CHEMICAL COMPOUNDS AND PROCESSES | LTC4S, HNMT, SQLE | CHRNB2 4418/4885CHRNA4 4294/4885CA12 353/4885 |
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | CHRNB2 4112/4885CHRNA4 4373/4885CA12 484/4885 |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | CHRNB2 4112/4885CHRNA4 4373/4885CA12 484/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | CHRNB2 4496/4885CHRNA4 4278/4885CA12 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.